Physician profile
Efrain Reisin
NPI 1750302774
$2,371.67
in general payments reported to CMS, 2019-2025
20 companies · $467 in 2025
The $467 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $449 · 2020: $23.55 · 2021: $20.46 · 2022: $529 · 2023: $647 · 2024: $235 · 2025: $467.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,349.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,349.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $605.34 | 2022-2025 | Acthar, Terlivaz |
| Amgen INC. | $357.85 | 2019-2025 | Tavneos |
| Vifor Pharma, INC. | $247.44 | 2019-2022 | |
| Genzyme Corporation | $148.73 | 2019-2022 | |
| Horizon Therapeutics Plc | $124.99 | 2023 | Krystexxa |
| Glaxosmithkline, LLC. | $122.22 | 2022-2023 | |
| Alexion Pharmaceuticals, INC. | $121.87 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $100.23 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $99.53 | 2022 | |
| Aurinia Pharma U.S., INC. | $98.39 | 2025 | Lupkynis |
| Nxstage Medical, INC. | $73.16 | 2019 | |
| Calliditas Therapeutics US INC. | $72.23 | 2023 | Tarpeyo |
| Fresenius USA Marketing, INC. | $57.80 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $43.54 | 2019-2021 | |
| Travere Therapeutics, INC. | $30.52 | 2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $25.60 | 2025 | Vafseo |
| Astrazeneca Pharmaceuticals LP | $23.55 | 2020 | |
| Daiichi Sankyo INC. | $18.68 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Efrain Reisin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.